Try our beta test site
123 studies found for:    "Myelodysplastic Syndromes" | Germany
Show Display Options
Rank Status Study
1 Completed Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)
Conditions: Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention: Drug: 5-Azacytidin
2 Recruiting ACE-536 Extension Study - Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: ACE-536
3 Completed APG101 in Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Interventions: Drug: Treatment with APG101;   Procedure: Bone marrow collection;   Procedure: Blood drawings
4 Completed Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload
Conditions: Myelodysplastic Syndromes;   Transfusion Dependent Iron Overload
Intervention: Drug: ICL670/Deferasirox
5 Recruiting Study for Epidemiology and Characterization of Myelodysplastic Syndromes (MDS) and Juvenile Myelomonocytic Leucemia (JMML) in Childhood
Conditions: Myelodysplastic Syndromes;   Juvenile Myelomonocytic Leukemia
Intervention:
6 Recruiting Study of ACE-536 for the Treatment of Anemia in Patients With Myelodysplastic Syndromes (MDS)
Condition: Anemia
Intervention: Drug: ACE-536
7 Unknown  Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome
Conditions: Leukemia;   Myelodysplastic/Myeloproliferative Neoplasms
Interventions: Drug: cytarabine;   Drug: mercaptopurine;   Other: laboratory biomarker analysis;   Procedure: allogeneic bone marrow transplantation;   Procedure: biopsy;   Procedure: peripheral blood stem cell transplantation
8 Not yet recruiting Study Investigating the Interactions of Bone and Hematopoiesis in the Elderly
Condition: Myelodysplastic Syndromes
Intervention: Other: Observational
9 Completed Peripheral Blood (PB) Versus Bone Marrow (BM) in Allogeneic Stem Cell Transplantation
Conditions: Acute Leukemia;   Chronic Myelogenous Leukemia;   Myelodysplastic Syndrome
Interventions: Procedure: Bone marrow transplantation;   Procedure: Peripheral blood stem cell transplantation
10 Recruiting Prophylactic Application of Donor-derived TCM After Allogeneic HSCT
Conditions: Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes
Intervention: Biological: TCM allogeneic humane central memory T cells, cryopreserved
11 Terminated Exjade-Early-Trial
Condition: Myelodysplastic Syndromes
Intervention: Drug: Deferasirox (Novartis Pharma)
12 Recruiting CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.
Conditions: Myelodysplastic Syndromes;   Acute Leukemia
Intervention: Drug: CIK-Cells
13 Completed Non-interventional Study With Azacitidin (Vidaza®)
Conditions: MDS;   AML;   CMMOL
Intervention:
14 Terminated Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes
Conditions: Myelodysplastic Syndromes;   Acute Myelogenous Leukemia
Interventions: Drug: Azacitidine;   Drug: Lenalidomide
15 Unknown  WT1 Peptide Vaccination in Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukemia;   Myelodysplastic Syndrome
Intervention: Biological: WT1 126-134 peptide
16 Terminated Efficacy and Tolerability of the Combination of Valproic Acid and Lenalidomide in the Treatment of Patients With Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome MDS
Interventions: Drug: Valproic aicd;   Drug: Lenalidomide
17 Recruiting Azacitidine, Lenalidomide and DLI as Salvage Therapy for MDS, CMML and sAML Relapsing After Allo-HSCT
Conditions: Leukemia, Myeloid, Acute;   Myelodysplastic Syndromes;   Leukemia, Myelomonocytic, Chronic
Interventions: Drug: Lenalidomide;   Drug: Azacitidine;   Biological: Donor Lymphocyte Infusions
18 Recruiting Study With Azacitidine in Pediatric Subjects With Newly Diagnosed Advanced Myelodysplastic Syndrome (MDS) and Juvenile Myelomonocytic Leukemia (JMML)
Conditions: Myelodysplastic Syndrome;   Leukemia, Myelomonocytic, Juvenile
Intervention: Drug: Azacitidine
19 Unknown  ClAraC or FLAMSA Followed by Stem Cell Transplantation to Treat High Risk AML or Advanced MDS
Conditions: Acute Myeloid Leukemia;   MDS
Interventions: Drug: Clofarabine, ara-C;   Drug: FLAMSA
20 Recruiting Study to Evaluate Imetelstat (JNJ-63935937) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Interventions: Drug: Imetelstat;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.